![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: IRF7 |
Gene summary for IRF7 |
![]() |
Gene information | Species | Human | Gene symbol | IRF7 | Gene ID | 3665 |
Gene name | interferon regulatory factor 7 | |
Gene Alias | IMD39 | |
Cytomap | 11p15.5 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q92985 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3665 | IRF7 | C21 | Human | Oral cavity | OSCC | 1.02e-59 | 2.02e+00 | 0.2678 |
3665 | IRF7 | C30 | Human | Oral cavity | OSCC | 1.75e-50 | 2.38e+00 | 0.3055 |
3665 | IRF7 | C38 | Human | Oral cavity | OSCC | 5.34e-12 | 1.22e+00 | 0.172 |
3665 | IRF7 | C43 | Human | Oral cavity | OSCC | 1.38e-13 | 3.96e-01 | 0.1704 |
3665 | IRF7 | C46 | Human | Oral cavity | OSCC | 1.28e-35 | 8.85e-01 | 0.1673 |
3665 | IRF7 | C51 | Human | Oral cavity | OSCC | 2.04e-35 | 1.63e+00 | 0.2674 |
3665 | IRF7 | C57 | Human | Oral cavity | OSCC | 5.28e-31 | 9.21e-01 | 0.1679 |
3665 | IRF7 | C06 | Human | Oral cavity | OSCC | 2.18e-05 | 8.10e-01 | 0.2699 |
3665 | IRF7 | C07 | Human | Oral cavity | OSCC | 4.17e-02 | 6.49e-01 | 0.2491 |
3665 | IRF7 | C08 | Human | Oral cavity | OSCC | 1.45e-22 | 6.76e-01 | 0.1919 |
3665 | IRF7 | C86 | Human | Oral cavity | OSCC | 1.25e-02 | 4.64e-01 | 0.161 |
3665 | IRF7 | C09 | Human | Oral cavity | OSCC | 1.39e-32 | 8.45e-01 | 0.1431 |
3665 | IRF7 | LN22 | Human | Oral cavity | OSCC | 9.71e-10 | 9.41e-01 | 0.1733 |
3665 | IRF7 | LN46 | Human | Oral cavity | OSCC | 1.80e-58 | 2.33e+00 | 0.1666 |
3665 | IRF7 | LP15 | Human | Oral cavity | LP | 7.46e-04 | 1.01e+00 | 0.2174 |
3665 | IRF7 | LP17 | Human | Oral cavity | LP | 1.02e-06 | 7.60e-01 | 0.2349 |
3665 | IRF7 | EOLP-1 | Human | Oral cavity | EOLP | 1.90e-02 | 3.01e-01 | -0.0202 |
3665 | IRF7 | SYSMH2 | Human | Oral cavity | OSCC | 2.97e-32 | 9.99e-01 | 0.2326 |
3665 | IRF7 | SYSMH3 | Human | Oral cavity | OSCC | 1.92e-20 | 7.47e-01 | 0.2442 |
3665 | IRF7 | SYSMH4 | Human | Oral cavity | OSCC | 9.57e-09 | 1.91e-01 | 0.1226 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
GO:0030522110 | Esophagus | ESCC | intracellular receptor signaling pathway | 170/8552 | 265/18723 | 8.58e-10 | 2.09e-08 | 170 |
GO:0030099111 | Esophagus | ESCC | myeloid cell differentiation | 232/8552 | 381/18723 | 1.22e-09 | 2.90e-08 | 232 |
GO:003434013 | Esophagus | ESCC | response to type I interferon | 48/8552 | 58/18723 | 6.18e-09 | 1.26e-07 | 48 |
GO:00603375 | Esophagus | ESCC | type I interferon signaling pathway | 41/8552 | 50/18723 | 1.35e-07 | 2.17e-06 | 41 |
GO:00713575 | Esophagus | ESCC | cellular response to type I interferon | 42/8552 | 52/18723 | 2.15e-07 | 3.30e-06 | 42 |
GO:00028318 | Esophagus | ESCC | regulation of response to biotic stimulus | 191/8552 | 327/18723 | 2.12e-06 | 2.45e-05 | 191 |
GO:000257317 | Esophagus | ESCC | myeloid leukocyte differentiation | 128/8552 | 208/18723 | 2.75e-06 | 3.15e-05 | 128 |
GO:00607595 | Esophagus | ESCC | regulation of response to cytokine stimulus | 103/8552 | 162/18723 | 3.14e-06 | 3.53e-05 | 103 |
GO:00019595 | Esophagus | ESCC | regulation of cytokine-mediated signaling pathway | 95/8552 | 150/18723 | 9.48e-06 | 9.04e-05 | 95 |
GO:003952813 | Esophagus | ESCC | cytoplasmic pattern recognition receptor signaling pathway in response to virus | 28/8552 | 34/18723 | 1.21e-05 | 1.12e-04 | 28 |
GO:00603385 | Esophagus | ESCC | regulation of type I interferon-mediated signaling pathway | 29/8552 | 36/18723 | 1.91e-05 | 1.67e-04 | 29 |
GO:003248112 | Esophagus | ESCC | positive regulation of type I interferon production | 42/8552 | 58/18723 | 3.27e-05 | 2.70e-04 | 42 |
GO:009858613 | Esophagus | ESCC | cellular response to virus | 56/8552 | 84/18723 | 8.20e-05 | 6.01e-04 | 56 |
GO:00326084 | Esophagus | ESCC | interferon-beta production | 40/8552 | 56/18723 | 8.36e-05 | 6.08e-04 | 40 |
GO:00326484 | Esophagus | ESCC | regulation of interferon-beta production | 40/8552 | 56/18723 | 8.36e-05 | 6.08e-04 | 40 |
GO:003247912 | Esophagus | ESCC | regulation of type I interferon production | 61/8552 | 95/18723 | 2.05e-04 | 1.29e-03 | 61 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa05167211 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
hsa0516425 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa0520325 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
hsa05417211 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa051609 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
hsa051619 | Esophagus | ESCC | Hepatitis B | 108/4205 | 162/8465 | 7.68e-06 | 4.15e-05 | 2.12e-05 | 108 |
hsa051629 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
hsa0462122 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa046234 | Esophagus | ESCC | Cytosolic DNA-sensing pathway | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
hsa0516937 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0516738 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
hsa0516435 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa0520335 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
hsa05417310 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa0516016 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
hsa0516114 | Esophagus | ESCC | Hepatitis B | 108/4205 | 162/8465 | 7.68e-06 | 4.15e-05 | 2.12e-05 | 108 |
hsa0516213 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
hsa0462132 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa0462311 | Esophagus | ESCC | Cytosolic DNA-sensing pathway | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IRF7 | SNV | Missense_Mutation | novel | c.1313N>T | p.Ser438Phe | p.S438F | Q92985 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
IRF7 | SNV | Missense_Mutation | novel | c.1262N>A | p.Arg421Lys | p.R421K | Q92985 | protein_coding | tolerated(0.21) | benign(0.079) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
IRF7 | SNV | Missense_Mutation | rs375250292 | c.676G>C | p.Glu226Gln | p.E226Q | Q92985 | protein_coding | tolerated(0.57) | benign(0.015) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
IRF7 | SNV | Missense_Mutation | novel | c.1487C>G | p.Ser496Cys | p.S496C | Q92985 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-VS-A9UC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
IRF7 | deletion | Frame_Shift_Del | novel | c.1028_1085delNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN | p.Ala343GlyfsTer103 | p.A343Gfs*103 | Q92985 | protein_coding | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | ||
IRF7 | insertion | Frame_Shift_Ins | rs746222183 | c.646_647insG | p.Ala216GlyfsTer199 | p.A216Gfs*199 | Q92985 | protein_coding | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | ||
IRF7 | SNV | Missense_Mutation | novel | c.1541N>C | p.Gln514Pro | p.Q514P | Q92985 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
IRF7 | SNV | Missense_Mutation | c.446N>T | p.Thr149Met | p.T149M | Q92985 | protein_coding | tolerated(0.26) | benign(0.025) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
IRF7 | SNV | Missense_Mutation | c.593N>G | p.Gln198Arg | p.Q198R | Q92985 | protein_coding | deleterious(0) | possibly_damaging(0.559) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
IRF7 | SNV | Missense_Mutation | rs786205223 | c.1267N>G | p.Phe423Val | p.F423V | Q92985 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |